Eric Carlson is a partner in Goodwin’s Private Equity group. He represents private equity and venture capital firms, operating companies and investors in a broad range of strategic transactions, including leveraged buyouts, carve-outs, exits, growth equity financings and general corporate and governance matters.
Experience
Eric has advised clients on domestic and cross-border transactions across a range of industries. His recent experience includes advising:
- Ampersand Capital Partners in its acquisition of a commercial PEGylation reagent manufacturing business from Nektar Therapeutics (NASDAQ: NKTR)
- Ampersand Capital Partners in its acquisitions of ALPCO, iuvo Biosciences, Leinco Technologies, and StageBio
- Charlesbank Capital Partners in its acquisitions of MB2 Dental, MDVIP, Tecomet and Hearthside Food Solutions.
- Genezen in its acquisition of a manufacturing facility and commercial gene therapy business from uniQure (NASDAQ: QURE)
- Fresenius Medical Care in the sale of its multi-state platform of urgent care clinics
- Fresenius Medical Care in the sale of its outpatient cardiovascular clinics business to United Healthcare Group
- Mitokinin in its option-to-acquire sale to and research collaboration with AbbVie (NYSE: ABBV)
- Nexcelom Biosciences in its sale to PerkinElmer (NYSE: PKI)
- Sheehan Family Companies in the sale of its multi-state beverage distribution business
- T.A. Associates in its acquisitions of AffiniPay and MAV Beauty Brands
- Vibalogics in its sale to Recipharm
- Mission BioCapital in its investments in several early-stage life sciences companies, including AllinBio, Eikonizo Therapeutics, Immunos Therapeutics, and SiteOne Therapeutics
- Ampersand Capital Partners in growth investments in AnaBios, Kedrion Biopharma and Vernal Biosciences
- Phosphorex in a growth equity financing from NOF Corporation (OTCMKTS: NOFCF)
Credentials
Education
JD2009
Suffolk University School of Law
(magna cum laude)
BS2002
Babson College
(magna cum laude)
Admissions
Bars
- Massachusetts